PEGylated Gold Nanoprisms for Photothermal Therapy at Low Laser Power Density

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户:skywalker0123
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective: Photothermal therapy (PTT) has emerge as a promising way to treat cancer with minimal invasion and high selectivity.The purpose of this study was to synthesis gold nanoprisms (GNPs) as a new kind of photothermal agents, and test their photothermal therapeutic efficacy on breast cancers.
其他文献
Objective: The effects of antituberculosis treatment in patients with coexistence of lung cancer and pulmonary tuberculosis has not been known well.The aim of this study was to investigate the curativ
Objective: Hsa-miRNA-206 (miR-206), highly expressed inskeletal muscle, has recently been discovered to have anticancer properties indifferent tissues.However, the role of miR-206 on lung cancer is st
目的:讨论颅内室管膜瘤的临床特点和治疗转归。方法:回顾性分析2009年1月~2012年6月收治的经病理证实的30例颅内室管膜瘤术后放射治疗患者的临床资料,观察疗效并结合文献进行分析。
Objective: MicroRNA plays a crucial role in development and progression of multiple malignancies.However, the mechanisms of microRNA in cancer are not totally clear.
Objective: To evaluate the clinical activity of angiogenesis inhibitor Endostar (rh-endostatin) in combination with continued EGFR-TKIs (including erlotinib, gefitinib and IcotinibO) for advanced NSCL
Objective: To evaluate the efficacy of treatment with dose-escalated icotinib after resistance to routine dose of icotinib for the patients of the advanced non-smoll cell lung cancer.
目的:近年来针对肿瘤内部异质性的探索成为了新的研究热点。大多数肺癌在最初阶段对治疗一定程度的有效反应。经过一段时期后,残留的癌细胞亚群可致肿瘤复发或者转移。复发瘤的癌细胞遗传不稳定性增强,给临床治疗带来不小的障碍。
目的:探讨埃克替尼靶向治疗期间适时手术干预治疗非小细胞肺癌的可行性。方法:对我科经埃克替尼靶向治疗后在不同时机采取手术干预的10例患者进行回顾性分析。结果:10例患者经埃克替尼靶向治疗后均施行手术干预治疗,其中行左全肺切除1例,肺叶切除6例,局部切除3例。
目的:在既往报道中,典型的剂量-体积直方图(DVH)参数是肺癌患者放射治疗后发生放射性肺炎(RP)的预测因素。然而,上述剂量学因素和RP这二者相关的讨论仅在局限的治疗环境中。因此,在本文中我们回顾性评估了DVH对术后放射治疗(PORT)后的肺癌患者发生急性重度放射性肺炎(ASRP)可能存在的预测作用。
Objective: Pyruvatekinase M2 (PKM2) is the key enzyme in Warburg effect and was reported to be involved in metabolic pathways of tumor cells response to chemotherapeutic drugs recently.